BioSpace News Archive

Earlier this week, the FDA announced new steps to modernize FDA’s 510(k) clearance pathway, used for low- to moderate-risk devices that are substantially equivalent to a device already on the market, known as a predicate device.

Bausch Health Companies Inc. announced today that it has entered into an incremental term loan facility amendment (the “Incremental Amendment”) to its credit agreement, pursuant to which Valeant Pharmaceuticals International (“VPI”), a Delaware corporation and a wholly owned indirect subsidiary of the Company, borrowed $1,500,000,000 of new term B loans.

2Q19 Added 22,908 New Subscribers

Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company, today reported that data from three abstracts—including an oral presentation—were accepted for presentation at the 60th American Society of Hematology Annual Meeting (ASH 2018)

Aidoc, a leading provider of AI solutions for radiologists, revealed today that their always-on solution for automatic flagging and prioritization of critical CT cases is in full use at the University of Rochester Medicine, saving lives by ensuring that urgent cases are quickly diagnosed and treated.

Vivos Therapeutics, a company focused on addressing the root causes of mild-to-moderate sleep apnea, announced Brad Amman has joined the company as Chief Financial Officer.

Insurer offers educational program to close knowledge gap and encourage addiction prevention, treatment and recovery, in an effort to help curb the opioid crisis

Award-winning hazardous drug compounding system, Equashield Pro, will demo at American Society of Health System Pharmacy (ASHP) Midyear Meeting in Anaheim, CA

Solaraze® Gel, 3% is indicated for the topical treatment of actinic keratoses.

Therapix. (“Therapix” or the “Company”) (NASDAQ: TRPX) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announces that the Company has entered into a securities purchase agreement in a private placement with YA II PN Ltd. (the “Investor”), a fund managed by Yorkville Advisors Global, for up to $2.5 million in principal amount of unsecured convertible debentures (the “Debentures”).